如何优化吉西他滨在晚期胆系肿瘤中的应用

How to optimize the application of gemcitabine on patients with advanced biliary tract carcer

胆系肿瘤(BTC)主要包括胆囊癌、肝内胆管癌和肝外胆管癌,其中前两种近年来发病率不断攀升,仅有约10%的患者有根治性切除的机会。对于晚期胆系肿瘤,吉西他滨联合顺铂是目前一线治疗的"金标准",但越来越多的临床实践发现以吉西他滨为主的其他联合方式或许疗效更优。如何优化吉西他滨的疗效已经成为胆系肿瘤一线治疗的热点和焦点,本文拟对该领域作一综述。

Biliary tract cancer （ BTC ） mainly includes gallbladder cancers （ GBC）, intrahepatic and extrahepatic cancers （ ICC and ECC） with the rising morbidity of the first two kinds recently, and only about 10% patients have opportunity of radical resection. Gemcitabine combined with cisplatin now has been recognized as the ＂golden standard＂ first-line regimen to those with advanced stage BTC. More and more clinical observations or practices presently show that other gecitabine-based combination chemotherapy regimens perhaps have advantages compared to with cisplatin-combination. This review focuses on how to optimize the gemcibatine-based first- line therapy of patients with advanced BTC.